Nasus Pharma Ltd
NSRX · XNYSCIK 2029039fmd_0KYDMDCKS0PV5HFFMNXJQWYKMCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Dec 31, 2025, 5 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | – | – | 1,235 |
| Research and development | 1 | 0 | 2 |
| Total operating expenses | 1 | 1 | 5 |
| Operating income | (1) | (1) | (5) |
| Interest expense | 0 | 0 | (0) |
| Net income from continuing operations | (1) | (2) | (6) |
| Net income | (1) | (2) | (6) |
| Net income to common shareholders | 1 | 2 | 6 |